ES2193471T3 - Derivados de tiazol. - Google Patents

Derivados de tiazol.

Info

Publication number
ES2193471T3
ES2193471T3 ES98124670T ES98124670T ES2193471T3 ES 2193471 T3 ES2193471 T3 ES 2193471T3 ES 98124670 T ES98124670 T ES 98124670T ES 98124670 T ES98124670 T ES 98124670T ES 2193471 T3 ES2193471 T3 ES 2193471T3
Authority
ES
Spain
Prior art keywords
compounds
cells
well
tumor
revindication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98124670T
Other languages
English (en)
Inventor
Leo Alig
Albrecht Edenhofer
Kurt Hilpert
Thomas Weller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2193471T3 publication Critical patent/ES2193471T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS REPRESENTADOS POR LA FORMULA (I): ASI COMO A SALES FARMACEUTICAMENTE UTILES Y A ESTERES DE DICHOS COMPUESTOS, DONDE, R 1 , R 2 Y R 3 REPRESENTAN LO QUE SE MENCIONA EN LA REVINDICACION 1. DICHOS COMPUESTOS INHIBEN LA UNION DE PROTEINAS ADHESIVAS A LA SUPERFICIE DE DIFERENTES TIPOS DE CELULAS Y POR CONSIGUIENTE INFLUYEN EN LA INTERACCION ENTRE CELULAS Y EN LAS INTERACCIONES ENTRE MATRIZ Y CELULA. DICHOS COMPUESTOS PUEDEN UTILIZARSE EN FORMA DE PREPARACIONES FARMACEUTICAS PARA CONTROLAR O PREVENIR NEOPLASIAS, METASTASIS TUMORAL, CRECIMIENTO TUMORAL, OSTEOPOROSIS, ENFERMEDAD DE PAGET, RETINOPATIA DIABETICA, DEGENERACION MACULAR, RESTENOSIS QUE SURGE POSTERIORMENTE A UNA INTERVENCION VASCULAR, PSORIASIS, ARTRITIS, FIBROSIS, DISFUNCION RENAL, ASI COMO INFECCIONES CAUSADAS POR VIRUS, BACTERIAS U HONGOS.
ES98124670T 1998-01-02 1998-12-24 Derivados de tiazol. Expired - Lifetime ES2193471T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98100006 1998-01-02

Publications (1)

Publication Number Publication Date
ES2193471T3 true ES2193471T3 (es) 2003-11-01

Family

ID=8231229

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98124670T Expired - Lifetime ES2193471T3 (es) 1998-01-02 1998-12-24 Derivados de tiazol.

Country Status (29)

Country Link
US (3) US6100282A (es)
JP (1) JP3113237B2 (es)
KR (1) KR100312901B1 (es)
CN (1) CN1080720C (es)
AR (1) AR014949A1 (es)
AT (1) ATE233746T1 (es)
AU (1) AU720618B2 (es)
BR (1) BR9900006A (es)
CA (1) CA2257328C (es)
CO (1) CO4990934A1 (es)
DE (1) DE69811844T2 (es)
DK (1) DK0928790T3 (es)
ES (1) ES2193471T3 (es)
HR (1) HRP980645A2 (es)
HU (1) HUP9803040A3 (es)
ID (1) ID21936A (es)
IL (1) IL127785A (es)
MA (1) MA26591A1 (es)
NO (1) NO312067B1 (es)
NZ (2) NZ333590A (es)
PE (1) PE20000061A1 (es)
PL (1) PL330619A1 (es)
PT (1) PT928790E (es)
RU (1) RU2218337C2 (es)
SG (1) SG74686A1 (es)
TR (1) TR199802765A2 (es)
UY (1) UY25334A1 (es)
YU (1) YU61398A (es)
ZA (1) ZA9811925B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
IL142090A0 (en) 1998-10-22 2002-03-10 Hoffmann La Roche Thiazole derivatives
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
WO2001004103A1 (en) 1999-07-13 2001-01-18 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
US6759425B2 (en) * 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2001052847A1 (en) * 2000-01-19 2001-07-26 Alteon, Inc. Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
BR0208010A (pt) * 2001-03-12 2004-12-21 Avanir Pharmaceuticals Composto de benzimidazol para modulação de ige e inibição de proliferação celular
AR038703A1 (es) * 2002-02-28 2005-01-26 Novartis Ag Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
CN100491361C (zh) * 2003-01-27 2009-05-27 安斯泰来制药有限公司 噻唑衍生物及其作为vap-1抑制剂的用途
WO2005013950A2 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
US7652146B2 (en) * 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
CA2580725A1 (en) * 2004-09-20 2006-03-30 4Sc Ag Novel heterocyclic nf-kb inhibitors
KR100919905B1 (ko) * 2005-01-26 2009-10-06 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
US8716320B2 (en) * 2006-07-21 2014-05-06 Replidyne, Inc. Antibacteriall heterocyclic ureas
EP2200440B1 (en) 2007-07-23 2017-07-19 Crestone, Inc. Antibacterial amide and sulfonamide substituted heterocyclic urea compounds
WO2009015193A1 (en) * 2007-07-23 2009-01-29 Replidyne, Inc. Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds
AR075899A1 (es) * 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
CN102936257B (zh) * 2012-08-30 2016-03-30 齐鲁工业大学 一类含银的噻唑西弗碱配合物的结构、制备和用途
WO2019002074A1 (en) 2017-06-29 2019-01-03 Bayer Aktiengesellschaft THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PRMT5
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2009155B (en) * 1977-11-07 1982-07-21 Leo Pharm Prod Ltd Chemical compounds
FR2581063B1 (fr) 1985-04-30 1987-07-17 Chauvin Blache Lab Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique
JPS62123180A (ja) * 1985-11-21 1987-06-04 Otsuka Pharmaceut Factory Inc ｐ−アミノフエノ−ル誘導体
US5000775A (en) * 1985-12-31 1991-03-19 Monsanto Company 2-amino-4,5-disubstituted-oxazole/thiazole compounds as herbicide antidotes
JPS6348873A (ja) * 1986-08-19 1988-03-01 Toshiba Corp ガスレ−ザ発振装置
CA2037153A1 (en) * 1990-03-09 1991-09-10 Leo Alig Acetic acid derivatives
US5273982A (en) * 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
FI922867A7 (fi) * 1991-06-21 1992-12-22 Tanabe Seiyaku Co Dikarbonsyraderivat och foerfarande foer framstaellning av dem
AU646966B2 (en) * 1991-08-23 1994-03-10 Takeda Chemical Industries Ltd. 2-piperazinone compounds, their production and use
GB9125970D0 (en) * 1991-12-06 1992-02-05 Fujisawa Pharmaceutical Co New compounds
US5514643A (en) * 1993-08-16 1996-05-07 Lucky Ltd. 2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms
JPH0867676A (ja) * 1994-03-30 1996-03-12 Eisai Kagaku Kk 保護アミノチアゾリル酢酸誘導体
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
JPH08337579A (ja) * 1995-06-14 1996-12-24 Fujisawa Pharmaceut Co Ltd グアニジノチアゾ−ルおよびその抗潰瘍剤、ｈ２−受容体拮抗剤および抗菌剤としての用途
JPH09295974A (ja) * 1995-09-11 1997-11-18 Nippon Nohyaku Co Ltd アゾール誘導体、その用途及びその製造方法並びにその使用方法
NZ299242A (en) * 1995-09-11 1997-12-19 Nihon Nohyaku Co Ltd N-phenyl-n'-(phenyl substituted imidazol-5-yl, -oxazol-4-yl, and -thiazol-4-yl)urea derivatives
NZ331104A (en) * 1995-12-29 2000-03-27 Boehringer Ingelheim Ca Ltd Phenyl thiazole derivatives that inhibit herpes replication by inhibiting the herpes helicase primase enzyme complex
ATE244228T1 (de) * 1997-02-13 2003-07-15 Tokuyama Corp Verfahren zur herstellung von chloroacetylaminothiazoleaceticsäure derivate
MA26487A1 (fr) * 1997-04-29 2004-12-20 Smithkline Beecham Corp Heterocyclecetohydrazides inhibiteurs de proteases, procede pour leur preparation et compositions pharmaceutiques les contenant .
JP6348873B2 (ja) 2015-04-24 2018-06-27 株式会社ソフイア 遊技機

Also Published As

Publication number Publication date
CO4990934A1 (es) 2000-12-26
MA26591A1 (fr) 2004-12-20
DK0928790T3 (da) 2003-06-30
TR199802765A3 (tr) 1999-07-21
US6344562B1 (en) 2002-02-05
BR9900006A (pt) 2000-04-11
KR100312901B1 (ko) 2002-01-15
CA2257328A1 (en) 1999-07-02
HU9803040D0 (en) 1999-02-01
PL330619A1 (en) 1999-07-05
HUP9803040A3 (en) 2001-04-28
JP2000053664A (ja) 2000-02-22
ATE233746T1 (de) 2003-03-15
UY25334A1 (es) 2001-01-31
RU2218337C2 (ru) 2003-12-10
US6320054B1 (en) 2001-11-20
DE69811844D1 (de) 2003-04-10
IL127785A0 (en) 1999-10-28
US20020010316A1 (en) 2002-01-24
TR199802765A2 (xx) 1999-07-21
CA2257328C (en) 2006-05-09
YU61398A (sh) 2001-12-26
AR014949A1 (es) 2001-04-11
NZ333591A (en) 2000-05-26
NO986159L (no) 1999-07-05
HK1020953A1 (en) 2000-05-26
AU9614498A (en) 1999-07-22
IL127785A (en) 2004-09-27
NO986159D0 (no) 1998-12-28
ZA9811925B (en) 2000-06-29
CN1080720C (zh) 2002-03-13
CN1224718A (zh) 1999-08-04
HUP9803040A2 (hu) 2000-04-28
KR19990066925A (ko) 1999-08-16
SG74686A1 (en) 2000-08-22
PE20000061A1 (es) 2000-02-09
HRP980645A2 (en) 1999-10-31
AU720618B2 (en) 2000-06-08
NO312067B1 (no) 2002-03-11
DE69811844T2 (de) 2003-12-04
ID21936A (id) 1999-08-12
NZ333590A (en) 2000-05-26
US6100282A (en) 2000-08-08
JP3113237B2 (ja) 2000-11-27
PT928790E (pt) 2003-07-31

Similar Documents

Publication Publication Date Title
AR024703A1 (es) Benzazepinonas y quinazolinas
CA2257328A1 (en) Thiazole derivatives
MEP10408A (en) Platinum derivative pharmaceutical formulations
ES2194030T3 (es) Procedimiento para la preparacion de acido l-glutamico mediante fermentacion.
PT1274698E (pt) Perciquinina, metodo para a sua producao e sua utilizacao como medicamento
Manetta et al. Novel phosphonium salts displayin vitroandin vivocytotoxic activity against human ovarian cancer cell lines
EA200400476A1 (ru) Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
US6465512B2 (en) Leukemic cell growth inhibiting method
IL143666A0 (en) Prodrug compounds and process for preparation thereof
CN101300014A (zh) 通过靶向转运生物活性物质到线粒体中而对有机体产生作用的方法、实现该方法的药物组合物及用于此目的的化合物
EP1291362A4 (en) COMPLEX OF FOLIC ACID AND POLYSACCHARIDES, THE PRODUCTION THEREOF AND THE COMPLEX COMPRISING THE COMPOSITION COMPRISING THE ACTIVE INGREDIENT COMPOSITION
ES2176895T3 (es) Derivados de tiazol.
BRPI0410236A (pt) oxiarenos substituìdos
PE20011223A1 (es) Composicion farmaceutica que comprende pemetrexed y un antioxidante como monotioglicerol, l-cisteina y acido tioglicolico
ATE420099T1 (de) Medikament zur wachstumsinhibierung von tumoren
BR9908125A (pt) Composto, composto dimérico, composição farmacêutica, uso do composto, processo compreendendo inibir células de câncer, e, processo terapêutico
Gjetting et al. Effective Nanoparticle‐based Gene Delivery by a Protease Triggered Charge Switch
YU29201A (sh) Derivati tiazola
Floch et al. Transgene expression kinetics after transfection with cationic phosphonolipids in hematopoietic non adherent cells
AR008371A1 (es) Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
PL358328A1 (en) Cyclipostins, a method for their production and the use of the same
WO2023101993A3 (en) Segmented nucleic acids
ECSP993185A (es) Derivados de tiazol
DE69932164D1 (de) Polyanionische polymere mit verbesserter fusogenfähigkeit
IT1318547B1 (it) Impiego dell'aloe-emodin nel trattamento di patologie neoplastiche diorigine neuroectodermica.